logo-loader

Ixico set to return to double digit growth in 2022 as impact of Covid-19 on drug trials eases

Published: 06:49 11 Aug 2021 EDT

IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF) (LON:IXI) CFO Grant Nash joins Proactive London's Katie Pilbeam about returning to double-digit revenue growth again in 2022 as the impact of Covid-19 on drug trials eases and activity picks up again.

Nash explains that having enjoyed exceptional growth over recent years, industry-wide impacts of COVID-19 and the unexpected developments from their largest client's trials have had an impact but the market itself has not changed. 

As a result, Ixico now expects to report revenues of £8.7mln in the year to end September 2021 and underlying profits [EBITDA] of £1.2mln compared to revenues of £9.5mln and underlying profits of £1.3mln in  2020.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

25 minutes ago